uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. It also develops AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical therapeutic for congestive heart failure; AMT-021, a gene therapy, which has completed Phase I clinical trial for acute intermittent porphyria; AMT-110, a gene therapy that is in Phase I/II clinical trial for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, University of California San Francisco, Bristol-Myers Squibb, and 4D Molecular Therapeutics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
March 7, 2024
RegMed Investors (RMi) Closing Bell: drip, drip and drop share pricing
March 6, 2024
RegMed Investors (RMi) Closing Bell: a need for share pricing consistency to retain investors staying power
March 5, 2024
RegMed Investors (RMi) Closing Bell: a black swan versus a white swan; referring to different level of risk
March 1, 2024
RegMed Investors (RMi) Closing Bell: another knee-jerk reaction but, to our advantage
February 29, 2024
RegMed Investors (RMi) Closing Bell: investor jitters
February 28, 2024
RegMed Investors (RMi) Closing Bell: run from sector highs to cash as a portfolio value preservation strategy
February 28, 2024
RegMed Investors’ (RMi) pre-open: the rising tide eventually crests
February 23, 2024
RegMed Investors (RMi) Closing Bell: yesterday’s ups and downs were switching positions
February 22, 2024
RegMed Investors (RMi) Closing Bell: will the “elevation” trend stay a friend?
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors